Scopus BioPharma Inc.
DelistedCIK 1772028fmd_122S2NBS8E6NXTVCM7E3G49DW2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2023, 16 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Operating income
- (12)
- Net income
- (12)
- Free cash flow
- (8)
Latest quarter · Q1 FY2023
Millions- Total revenues
- 0
- Net income
- (3)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- n/m
Scopus BioPharma Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2023-04-14 · proof | |
| Operating income | -$11.7 million | -$27.6 million | 10-K 2023-04-14 · proof | |
| Net income | -$11.6 million | -$27 million | 10-K 2023-04-14 · proof | |
| Cash from operating activities | -$8.1 million | -$11.4 million | 10-K 2023-04-14 · proof | |
| Free cash flow | -$8.1 million | -$11.4 million | 10-K 2023-04-14 · proof | |
| Total assets | $392,265 | $8.2 million | -95.2% | 10-K 2023-04-14 · proof |
| Total liabilities | $7.5 million | $4.2 million | +78.8% | 10-K 2023-04-14 · proof |
| Cash and cash equivalents | $124,575 | $7.9 million | -98.4% | 10-K 2023-04-14 · proof |
- What was Scopus BioPharma Inc.'s revenue in fiscal 2022?
- Scopus BioPharma Inc. reported revenue of $0 for fiscal 2022 (the year ended Dec 31, 2022), against $0 the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was Scopus BioPharma Inc.'s operating income in fiscal 2022?
- Scopus BioPharma Inc. reported operating income of -$11.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$27.6 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was Scopus BioPharma Inc.'s net income in fiscal 2022?
- Scopus BioPharma Inc. reported net income of -$11.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$27 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was Scopus BioPharma Inc.'s cash from operating activities in fiscal 2022?
- Scopus BioPharma Inc. reported cash from operating activities of -$8.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$11.4 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was Scopus BioPharma Inc.'s free cash flow in fiscal 2022?
- Scopus BioPharma Inc. reported free cash flow of -$8.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -$11.4 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are Scopus BioPharma Inc.'s total assets?
- As of Dec 31, 2022, Scopus BioPharma Inc. reported total assets of $392,265, against $8.2 million a year earlier (-95.2%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are Scopus BioPharma Inc.'s total liabilities?
- As of Dec 31, 2022, Scopus BioPharma Inc. reported total liabilities of $7.5 million, against $4.2 million a year earlier (+78.8%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are Scopus BioPharma Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Scopus BioPharma Inc. reported cash and cash equivalents of $124,575, against $7.9 million a year earlier (-98.4%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1772028&period_type=annual&limit=5"Information only, not investment advice.